Regeneron Logo.jpg
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET | Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Regeneron Logo.jpg
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024 01:00 ET | Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
Pneumagen logo.jpg
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
May 23, 2024 07:00 ET | Pneumagen Ltd
 Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on...
Pneumagen logo.jpg
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
May 02, 2024 07:00 ET | Pneumagen Ltd
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
RS BioTherapeutics Logo.jpg
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
April 30, 2024 10:00 ET | RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
Jane Wright-Mitchell
RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board
April 25, 2024 10:00 ET | RS BioTherapeutics
RS BioTherapeutics is pleased to announce the addition of Jane Wright-Mitchell, Pharm.D., J.D. to the RS BioTherapeutics Business Advisory Board.
Global Interventional Pulmonology Market
Global Interventional Pulmonology Market Analysis Report 2024-2028: Robotic Bronchoscopy is Emerging as a Game Changer in the $5+ Billion Industry
April 16, 2024 07:32 ET | Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Pulmonology Market: Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ...
RS BioTherapeutics Logo.jpg
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
March 18, 2024 11:30 ET | RS BioTherapeutics
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit
Research Nester Logo.jpg
Chronic Disease Management Market revenue to reach USD 27 Billion by 2035, says Research Nester
March 13, 2024 07:30 ET | Research Nester
New York, March 13, 2024 (GLOBE NEWSWIRE) -- The global chronic disease management market size is projected to grow at a CAGR of over ~13% from 2023 to 2035. The market is expected to garner a...
Monaghan Medical Corporation
Monaghan Medical Corporation Attains ISO 14001 Certification for Environmental Management Excellence
February 27, 2024 07:00 ET | Monaghan Medical Corporation
Monaghan Medical Corporation is proud to have achieved ISO 14001 certification